NZ budget boosts R&D
20 May, 2005 by Graeme O'NeillNew Zealand's biotechnology industry has welcomed a "solid incremental improvement" in S&T funding in this week's NZ budget.
Govt R&D investment continues to slip
20 May, 2005 by Graeme O'NeillThe Federation of Australian Scientific and Technological Societies (FASTS) has warned that Commonwealth investment in research and development will drop below 0.6 per cent of gross domestic product as a result this month's federal budget.
'Heavy-hearted' Smith steps down from Amrad
20 May, 2005 by Renate KrellePete Smith has resigned as CEO of Amrad (ASX:AML), along with chairman Bob Moses as chairman, following a board meeting yesterday.
Chief scientist quits
17 May, 2005 by Ruth BeranChief scientist, Dr Robin Batterham, has accepted a full time position with Rio Tinto and will not seek reappointment as Australia's senior science advisor for a third term.
Back into the abyss: biotech hits funding crunch
12 May, 2005 by Ruth BeranBiotech companies which have failed to raise enough capital to see them through to the next funding cycle might expire as a funding drought sets in, and blame "shocking" market conditions for forcing them to abandon or change their plans.
Industry welcomes govt's VC review commitment
11 May, 2005 by Ruth BeranThe federal government has used last night's budget to confirm its 2004 election commitment to reviewing the venture capital industry in Australia.
Minomic in deal with Hong Kong's CK Life Sciences
11 May, 2005 by Renate Krelle and Ruth BeranPrivate Sydney proteomics company Minomic has signed an agreement with a biotech backed by Hong Kong's billion-dollar Cheung Kong Group to collaborate on one of the biotech's anti-cancer compounds.
Superannuation fund investment boosts Uniseed
10 May, 2005 by Ruth BeranWestern Australia's biggest private sector superannuation fund, Westscheme, has signed a AUD$15 million partnership with university based pre-seed venture fund Uniseed.
GBS closes $145m venture fund
10 May, 2005 by Renate KrelleMelbourne venture capital company GBS Venture Partners has announced the close of its GBS BioVentures III Fund. The fund raised AUD$145 million, making it more than twice as large as GBS's previous funds, and well over its original target of $120 million.
Garrett reappointed as CSIRO chief
09 May, 2005 by Staff WritersDr Geoff Garrett has been reappointed as chief executive of the Commonwealth Scientific and Industrial Research Organisation's (CSIRO).
New shareholder for Bionomics
06 May, 2005 by Ruth BeranAdelaide company Bionomics (ASX:BNO) has seen a major change in its shareholding in the past few weeks, with Queensland Investment Corporation ceasing to be a substantial shareholder and Laurence Freedman's Link Traders filling the gap.
We're not getting out of biotech: QIC
06 May, 2005 by Renate KrelleRumours have abounded in recent weeks that Queensland Investment Corporation- which over the last three years has emerged as the largest single investor in Australian biotechnology - is selling out of the sector, prompted by the funds' sale of its shareholding in biotechs Rockeby Biomed (ASX:RBT), Biodiem (ASX:BDM) and Bionomics (ASX:BNO), and reduction of its stake in Eiffel (ASX:EIF).
Cussen resigns from Eiffel
05 May, 2005 by Renate KrelleChristine Cussen has resigned from her role as chief executive of drug re-engineering company Eiffel (ASX:EIF), at a time when the company's share price has dipped below $0.04 - more than two thirds below its level in January of around $0.12.
Axon, C3 alumni among Clunies Ross winners
03 May, 2005 by Ruth BeranBioscience entrepreneurs, including Axon Instruments founder Alan Finkel and Fiona Wood and Marie Stoner of Clinical Cell Culture, have dominated the winners' circle at this year's ATSE Clunies Ross Awards.
US ponders loosening NIH ethics rules
29 April, 2005 by Staff WritersStrict new ethics rules imposed on National Institutes of Health staff to prevent lucrative deals with drug companies may be loosened if warranted, Health and Human Services Secretary Mike Leavitt has said.
